Literature DB >> 27696668

The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes.

Ulrich Rohde1,2, Cecilie A Federspiel1, Peter Vilmann3, Ebbe Langholz4, Steffen U Friis4, Martin Krakauer5, Jens F Rehfeld6, Jens J Holst2, Tina Vilsbøll1,7, Filip K Knop1,2,7.   

Abstract

AIMS: The duodenal-jejunal bypass sleeve ((DJBS) or EndoBarrier Gastrointestinal Liner) induces weight loss in obese subjects and may improve glucose homeostasis in patients with type 2 diabetes (T2D). To explore the underlying mechanisms, we evaluated postprandial physiology including glucose metabolism, gut hormone secretion, gallbladder emptying, appetite and food intake in patients undergoing DJBS treatment.
MATERIAL AND METHODS: A total of 10 normal glucose-tolerant (NGT) obese subjects and 9 age-, body weight- and body mass index-matched metformin-treated T2D patients underwent a liquid mixed meal test and a subsequent ad libitum meal test before implantation with DJBS and 1 week (1w) and 26 weeks (26w) after implantation.
RESULTS: At 26w, both groups had achieved a weight loss of 6 to 7 kg. Postprandial glucagon-like peptide-1 (GLP-1) and peptide YY responses increased at 1w and 26w, but only in T2D subjects. In contrast, glucose-dependent insulinotropic polypeptide responses were reduced only by DJBS in the NGT group. Postprandial glucose, insulin, C-peptide, glucagon, cholecystokinin and gastrin responses were unaffected by DJBS in both groups. Satiety and fullness sensations were stronger and food intake was reduced at 1w in NGT subjects; no changes in appetite measures or food intake were observed in the T2D group. No effect of DJBS on postprandial gallbladder emptying was observed, and gastric emptying was not delayed.
CONCLUSIONS: DJBS-induced weight loss was associated with only marginal changes in postprandial physiology, which may explain the absence of effect on postprandial glucose metabolism.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990EndoBarrier gastrointestinal liner; gut hormones; obesity; observational study; postprandial glucose homeostasis; type 2 diabetes

Mesh:

Substances:

Year:  2016        PMID: 27696668     DOI: 10.1111/dom.12800

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  4 in total

Review 1.  Medical devices for the treatment of obesity.

Authors:  Phong Ching Lee; John Dixon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-07-12       Impact factor: 46.802

Review 2.  Endoscopic bariatrics: current therapies and future directions.

Authors:  Debashis Reja; Clark Zhang; Avik Sarkar
Journal:  Transl Gastroenterol Hepatol       Date:  2022-04-25

3.  Does Bypass of the Proximal Small Intestine Impact Food Intake, Preference, and Taste Function in Humans? An Experimental Medicine Study Using the Duodenal-Jejunal Bypass Liner.

Authors:  Madhawi M Aldhwayan; Werd Al-Najim; Aruchuna Ruban; Michael Alan Glaysher; Brett Johnson; Navpreet Chhina; Georgios K Dimitriadis; Christina Gabriele Prechtl; Nicholas A Johnson; James Patrick Byrne; Anthony Peter Goldstone; Julian P Teare; Carel W Le Roux; Alexander Dimitri Miras
Journal:  Nutrients       Date:  2022-05-20       Impact factor: 6.706

Review 4.  The EndoBarrier: Duodenal-Jejunal Bypass Liner for Diabetes and Weight Loss.

Authors:  Aruchuna Ruban; Hutan Ashrafian; Julian P Teare
Journal:  Gastroenterol Res Pract       Date:  2018-07-26       Impact factor: 2.260

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.